| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8508106 | Actualités Pharmaceutiques | 2018 | 6 Pages |
Abstract
The treatment of rheumatoid polyarthritis is based on the early prescribing of an effective long-term treatment such as methotrexate. However, some patients only respond partially, or not at all, to current treatments. New immunosuppressors such as Janus kinase inhibitors are therefore welcome. Tolerance studies are necessary in order to improve the way the potential risks of these medicines are identified and assessed.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Jacques (Professeur des Universités), Sébastien (Professeur des Universités),